JP2009515553A - 癌の予知および予後と、癌治療のモニタリング - Google Patents
癌の予知および予後と、癌治療のモニタリング Download PDFInfo
- Publication number
- JP2009515553A JP2009515553A JP2008541268A JP2008541268A JP2009515553A JP 2009515553 A JP2009515553 A JP 2009515553A JP 2008541268 A JP2008541268 A JP 2008541268A JP 2008541268 A JP2008541268 A JP 2008541268A JP 2009515553 A JP2009515553 A JP 2009515553A
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- sample
- vegf
- patient
- svegfr
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 112
- 201000011510 cancer Diseases 0.000 title claims abstract description 93
- 238000011282 treatment Methods 0.000 title claims abstract description 41
- 238000012544 monitoring process Methods 0.000 title claims description 12
- 238000004393 prognosis Methods 0.000 title abstract description 12
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims abstract description 61
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims abstract description 61
- 239000000090 biomarker Substances 0.000 claims abstract description 32
- 108090000623 proteins and genes Proteins 0.000 claims description 153
- 239000000523 sample Substances 0.000 claims description 141
- 238000000034 method Methods 0.000 claims description 133
- 230000014509 gene expression Effects 0.000 claims description 106
- 102000004169 proteins and genes Human genes 0.000 claims description 62
- 210000001519 tissue Anatomy 0.000 claims description 59
- 108020004999 messenger RNA Proteins 0.000 claims description 34
- 150000001875 compounds Chemical class 0.000 claims description 32
- 239000003795 chemical substances by application Substances 0.000 claims description 25
- 238000002493 microarray Methods 0.000 claims description 23
- 230000000694 effects Effects 0.000 claims description 22
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 claims description 21
- 239000005511 L01XE05 - Sorafenib Substances 0.000 claims description 21
- 229960003787 sorafenib Drugs 0.000 claims description 21
- 210000002381 plasma Anatomy 0.000 claims description 18
- 238000001574 biopsy Methods 0.000 claims description 17
- 210000004369 blood Anatomy 0.000 claims description 12
- 239000008280 blood Substances 0.000 claims description 12
- 102000040430 polynucleotide Human genes 0.000 claims description 12
- 108091033319 polynucleotide Proteins 0.000 claims description 12
- 239000002157 polynucleotide Substances 0.000 claims description 12
- 239000012472 biological sample Substances 0.000 claims description 11
- 208000032839 leukemia Diseases 0.000 claims description 11
- 239000013610 patient sample Substances 0.000 claims description 11
- 238000004458 analytical method Methods 0.000 claims description 10
- 230000004044 response Effects 0.000 claims description 10
- 206010039491 Sarcoma Diseases 0.000 claims description 9
- 210000002700 urine Anatomy 0.000 claims description 9
- 230000008859 change Effects 0.000 claims description 8
- 238000011065 in-situ storage Methods 0.000 claims description 8
- 239000002299 complementary DNA Substances 0.000 claims description 7
- 210000003734 kidney Anatomy 0.000 claims description 7
- 230000001575 pathological effect Effects 0.000 claims description 7
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 6
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 6
- 210000000056 organ Anatomy 0.000 claims description 6
- 210000002345 respiratory system Anatomy 0.000 claims description 6
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 5
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims description 5
- 208000006265 Renal cell carcinoma Diseases 0.000 claims description 5
- 201000000849 skin cancer Diseases 0.000 claims description 5
- 206010004593 Bile duct cancer Diseases 0.000 claims description 4
- 206010006187 Breast cancer Diseases 0.000 claims description 4
- 208000026310 Breast neoplasm Diseases 0.000 claims description 4
- 208000032612 Glial tumor Diseases 0.000 claims description 4
- 206010018338 Glioma Diseases 0.000 claims description 4
- 206010025323 Lymphomas Diseases 0.000 claims description 4
- 208000026900 bile duct neoplasm Diseases 0.000 claims description 4
- 210000000481 breast Anatomy 0.000 claims description 4
- 230000001684 chronic effect Effects 0.000 claims description 4
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 4
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims description 4
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims description 4
- 230000003211 malignant effect Effects 0.000 claims description 4
- 201000001441 melanoma Diseases 0.000 claims description 4
- 230000001850 reproductive effect Effects 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 4
- 210000000582 semen Anatomy 0.000 claims description 4
- 210000002966 serum Anatomy 0.000 claims description 4
- 210000003491 skin Anatomy 0.000 claims description 4
- 210000000626 ureter Anatomy 0.000 claims description 4
- 208000002008 AIDS-Related Lymphoma Diseases 0.000 claims description 3
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims description 3
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims description 3
- 208000007860 Anus Neoplasms Diseases 0.000 claims description 3
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 3
- 206010007953 Central nervous system lymphoma Diseases 0.000 claims description 3
- 208000017604 Hodgkin disease Diseases 0.000 claims description 3
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims description 3
- 206010061252 Intraocular melanoma Diseases 0.000 claims description 3
- 206010061336 Pelvic neoplasm Diseases 0.000 claims description 3
- 201000008199 Pleuropulmonary blastoma Diseases 0.000 claims description 3
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims description 3
- 206010060862 Prostate cancer Diseases 0.000 claims description 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 3
- 206010041067 Small cell lung cancer Diseases 0.000 claims description 3
- 208000021712 Soft tissue sarcoma Diseases 0.000 claims description 3
- 208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 claims description 3
- 208000024313 Testicular Neoplasms Diseases 0.000 claims description 3
- 206010057644 Testis cancer Diseases 0.000 claims description 3
- 206010046431 Urethral cancer Diseases 0.000 claims description 3
- 206010046458 Urethral neoplasms Diseases 0.000 claims description 3
- 201000005969 Uveal melanoma Diseases 0.000 claims description 3
- 206010047741 Vulval cancer Diseases 0.000 claims description 3
- 208000004354 Vulvar Neoplasms Diseases 0.000 claims description 3
- 210000004381 amniotic fluid Anatomy 0.000 claims description 3
- 239000013060 biological fluid Substances 0.000 claims description 3
- 210000001185 bone marrow Anatomy 0.000 claims description 3
- 210000004556 brain Anatomy 0.000 claims description 3
- 208000030224 brain astrocytoma Diseases 0.000 claims description 3
- 201000002143 bronchus adenoma Diseases 0.000 claims description 3
- 210000003679 cervix uteri Anatomy 0.000 claims description 3
- 210000001072 colon Anatomy 0.000 claims description 3
- 239000013068 control sample Substances 0.000 claims description 3
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 claims description 3
- 210000004696 endometrium Anatomy 0.000 claims description 3
- 210000003238 esophagus Anatomy 0.000 claims description 3
- 210000001508 eye Anatomy 0.000 claims description 3
- 208000024519 eye neoplasm Diseases 0.000 claims description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 claims description 3
- 210000002768 hair cell Anatomy 0.000 claims description 3
- 210000003128 head Anatomy 0.000 claims description 3
- 201000010536 head and neck cancer Diseases 0.000 claims description 3
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 claims description 3
- 210000004185 liver Anatomy 0.000 claims description 3
- 201000007270 liver cancer Diseases 0.000 claims description 3
- 208000014018 liver neoplasm Diseases 0.000 claims description 3
- 210000004698 lymphocyte Anatomy 0.000 claims description 3
- 208000025036 lymphosarcoma Diseases 0.000 claims description 3
- 210000000716 merkel cell Anatomy 0.000 claims description 3
- 206010061289 metastatic neoplasm Diseases 0.000 claims description 3
- 210000003739 neck Anatomy 0.000 claims description 3
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 3
- 201000002575 ocular melanoma Diseases 0.000 claims description 3
- 201000008968 osteosarcoma Diseases 0.000 claims description 3
- 210000001672 ovary Anatomy 0.000 claims description 3
- 210000000496 pancreas Anatomy 0.000 claims description 3
- 230000000849 parathyroid Effects 0.000 claims description 3
- 208000016800 primary central nervous system lymphoma Diseases 0.000 claims description 3
- 210000000664 rectum Anatomy 0.000 claims description 3
- 201000009410 rhabdomyosarcoma Diseases 0.000 claims description 3
- 210000003079 salivary gland Anatomy 0.000 claims description 3
- 201000008261 skin carcinoma Diseases 0.000 claims description 3
- 208000000587 small cell lung carcinoma Diseases 0.000 claims description 3
- 210000000813 small intestine Anatomy 0.000 claims description 3
- 208000017572 squamous cell neoplasm Diseases 0.000 claims description 3
- 210000002784 stomach Anatomy 0.000 claims description 3
- 201000003120 testicular cancer Diseases 0.000 claims description 3
- 210000001685 thyroid gland Anatomy 0.000 claims description 3
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 3
- 210000003932 urinary bladder Anatomy 0.000 claims description 3
- 208000037965 uterine sarcoma Diseases 0.000 claims description 3
- 201000005102 vulva cancer Diseases 0.000 claims description 3
- 206010027476 Metastases Diseases 0.000 claims description 2
- 238000001114 immunoprecipitation Methods 0.000 claims description 2
- 238000003757 reverse transcription PCR Methods 0.000 claims description 2
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 4
- 206010038389 Renal cancer Diseases 0.000 claims 4
- 201000010982 kidney cancer Diseases 0.000 claims 4
- 239000011230 binding agent Substances 0.000 claims 3
- 201000005787 hematologic cancer Diseases 0.000 claims 3
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims 3
- 239000012453 solvate Substances 0.000 claims 3
- LUBJCRLGQSPQNN-UHFFFAOYSA-N 1-Phenylurea Chemical compound NC(=O)NC1=CC=CC=C1 LUBJCRLGQSPQNN-UHFFFAOYSA-N 0.000 claims 2
- 208000003609 Bile Duct Adenoma Diseases 0.000 claims 2
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 claims 2
- 206010021042 Hypopharyngeal cancer Diseases 0.000 claims 2
- 206010056305 Hypopharyngeal neoplasm Diseases 0.000 claims 2
- 208000001126 Keratosis Diseases 0.000 claims 2
- 206010062038 Lip neoplasm Diseases 0.000 claims 2
- 206010025312 Lymphoma AIDS related Diseases 0.000 claims 2
- 208000000172 Medulloblastoma Diseases 0.000 claims 2
- 208000003445 Mouth Neoplasms Diseases 0.000 claims 2
- 208000001894 Nasopharyngeal Neoplasms Diseases 0.000 claims 2
- 206010061306 Nasopharyngeal cancer Diseases 0.000 claims 2
- 206010031096 Oropharyngeal cancer Diseases 0.000 claims 2
- 206010057444 Oropharyngeal neoplasm Diseases 0.000 claims 2
- 208000009565 Pharyngeal Neoplasms Diseases 0.000 claims 2
- 206010034811 Pharyngeal cancer Diseases 0.000 claims 2
- 201000000582 Retinoblastoma Diseases 0.000 claims 2
- 208000023915 Ureteral Neoplasms Diseases 0.000 claims 2
- 206010046392 Ureteric cancer Diseases 0.000 claims 2
- 210000001124 body fluid Anatomy 0.000 claims 2
- 239000010839 body fluid Substances 0.000 claims 2
- 201000005308 brain ependymoma Diseases 0.000 claims 2
- 230000002490 cerebral effect Effects 0.000 claims 2
- 201000007241 cutaneous T cell lymphoma Diseases 0.000 claims 2
- 210000000232 gallbladder Anatomy 0.000 claims 2
- 210000004392 genitalia Anatomy 0.000 claims 2
- 201000006866 hypopharynx cancer Diseases 0.000 claims 2
- 238000011221 initial treatment Methods 0.000 claims 2
- 201000008893 intraocular retinoblastoma Diseases 0.000 claims 2
- 201000006721 lip cancer Diseases 0.000 claims 2
- 230000002969 morbid Effects 0.000 claims 2
- 201000005962 mycosis fungoides Diseases 0.000 claims 2
- 201000008106 ocular cancer Diseases 0.000 claims 2
- 201000006958 oropharynx cancer Diseases 0.000 claims 2
- 208000025638 primary cutaneous T-cell non-Hodgkin lymphoma Diseases 0.000 claims 2
- 210000001215 vagina Anatomy 0.000 claims 2
- -1 4-pyridyloxy Chemical group 0.000 claims 1
- 206010003571 Astrocytoma Diseases 0.000 claims 1
- 201000009030 Carcinoma Diseases 0.000 claims 1
- 238000012286 ELISA Assay Methods 0.000 claims 1
- 208000002231 Muscle Neoplasms Diseases 0.000 claims 1
- 208000000821 Parathyroid Neoplasms Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 1
- 208000008383 Wilms tumor Diseases 0.000 claims 1
- 210000000988 bone and bone Anatomy 0.000 claims 1
- 208000035269 cancer or benign tumor Diseases 0.000 claims 1
- 230000000052 comparative effect Effects 0.000 claims 1
- 238000011156 evaluation Methods 0.000 claims 1
- 208000005017 glioblastoma Diseases 0.000 claims 1
- 238000003119 immunoblot Methods 0.000 claims 1
- 208000026037 malignant tumor of neck Diseases 0.000 claims 1
- 208000026045 malignant tumor of parathyroid gland Diseases 0.000 claims 1
- 230000009401 metastasis Effects 0.000 claims 1
- 201000002077 muscle cancer Diseases 0.000 claims 1
- 201000000050 myeloid neoplasm Diseases 0.000 claims 1
- 201000008026 nephroblastoma Diseases 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 230000001172 regenerating effect Effects 0.000 claims 1
- 201000011453 reproductive organ cancer Diseases 0.000 claims 1
- 208000015608 reproductive system cancer Diseases 0.000 claims 1
- 201000002510 thyroid cancer Diseases 0.000 claims 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 172
- 150000007523 nucleic acids Chemical class 0.000 description 140
- 102000039446 nucleic acids Human genes 0.000 description 120
- 108020004707 nucleic acids Proteins 0.000 description 120
- 108090000765 processed proteins & peptides Proteins 0.000 description 82
- 102000004196 processed proteins & peptides Human genes 0.000 description 74
- 229920001184 polypeptide Polymers 0.000 description 73
- 239000003550 marker Substances 0.000 description 72
- 238000009396 hybridization Methods 0.000 description 47
- 239000002773 nucleotide Substances 0.000 description 37
- 125000003729 nucleotide group Chemical group 0.000 description 37
- 238000012360 testing method Methods 0.000 description 34
- 229920002477 rna polymer Polymers 0.000 description 28
- 239000000047 product Substances 0.000 description 27
- 238000003556 assay Methods 0.000 description 24
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 description 22
- BJHCYTJNPVGSBZ-YXSASFKJSA-N 1-[4-[6-amino-5-[(Z)-methoxyiminomethyl]pyrimidin-4-yl]oxy-2-chlorophenyl]-3-ethylurea Chemical compound CCNC(=O)Nc1ccc(Oc2ncnc(N)c2\C=N/OC)cc1Cl BJHCYTJNPVGSBZ-YXSASFKJSA-N 0.000 description 21
- 108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 description 21
- 102000016549 Vascular Endothelial Growth Factor Receptor-2 Human genes 0.000 description 21
- 108091028043 Nucleic acid sequence Proteins 0.000 description 18
- 108020004711 Nucleic Acid Probes Proteins 0.000 description 15
- 108091008605 VEGF receptors Proteins 0.000 description 15
- 238000004422 calculation algorithm Methods 0.000 description 15
- 238000001514 detection method Methods 0.000 description 15
- 239000002853 nucleic acid probe Substances 0.000 description 15
- 239000003814 drug Substances 0.000 description 14
- 108091034117 Oligonucleotide Proteins 0.000 description 12
- 230000000295 complement effect Effects 0.000 description 12
- 102000004190 Enzymes Human genes 0.000 description 11
- 108090000790 Enzymes Proteins 0.000 description 11
- 230000027455 binding Effects 0.000 description 11
- 230000000875 corresponding effect Effects 0.000 description 11
- 229940079593 drug Drugs 0.000 description 11
- 229940088598 enzyme Drugs 0.000 description 11
- 238000004519 manufacturing process Methods 0.000 description 11
- 108020004414 DNA Proteins 0.000 description 10
- 102000053602 DNA Human genes 0.000 description 10
- 238000003018 immunoassay Methods 0.000 description 10
- 210000004881 tumor cell Anatomy 0.000 description 10
- 230000003321 amplification Effects 0.000 description 9
- 230000008901 benefit Effects 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 238000003199 nucleic acid amplification method Methods 0.000 description 9
- 238000003752 polymerase chain reaction Methods 0.000 description 9
- 230000001105 regulatory effect Effects 0.000 description 8
- 150000003384 small molecules Chemical class 0.000 description 8
- 239000007787 solid Substances 0.000 description 8
- 241000894007 species Species 0.000 description 8
- 239000000758 substrate Substances 0.000 description 8
- 108091026890 Coding region Proteins 0.000 description 7
- 101000851007 Homo sapiens Vascular endothelial growth factor receptor 2 Proteins 0.000 description 7
- 230000001413 cellular effect Effects 0.000 description 7
- 238000005516 engineering process Methods 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 108700020796 Oncogene Proteins 0.000 description 6
- 102000043276 Oncogene Human genes 0.000 description 6
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 6
- 230000002159 abnormal effect Effects 0.000 description 6
- 239000000556 agonist Substances 0.000 description 6
- 238000003491 array Methods 0.000 description 6
- 239000003153 chemical reaction reagent Substances 0.000 description 6
- 238000003745 diagnosis Methods 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 238000012216 screening Methods 0.000 description 6
- 238000013518 transcription Methods 0.000 description 6
- 230000035897 transcription Effects 0.000 description 6
- 238000002965 ELISA Methods 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 239000005557 antagonist Substances 0.000 description 5
- 239000002246 antineoplastic agent Substances 0.000 description 5
- 230000004071 biological effect Effects 0.000 description 5
- 239000000284 extract Substances 0.000 description 5
- 239000012634 fragment Substances 0.000 description 5
- 238000003364 immunohistochemistry Methods 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 238000000018 DNA microarray Methods 0.000 description 4
- 150000001413 amino acids Chemical group 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 230000002503 metabolic effect Effects 0.000 description 4
- 238000005070 sampling Methods 0.000 description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 238000005481 NMR spectroscopy Methods 0.000 description 3
- 206010061309 Neoplasm progression Diseases 0.000 description 3
- 108700025716 Tumor Suppressor Genes Proteins 0.000 description 3
- 102000044209 Tumor Suppressor Genes Human genes 0.000 description 3
- 229940024606 amino acid Drugs 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000002596 correlated effect Effects 0.000 description 3
- 210000004748 cultured cell Anatomy 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 230000037430 deletion Effects 0.000 description 3
- 238000012217 deletion Methods 0.000 description 3
- 238000002405 diagnostic procedure Methods 0.000 description 3
- 238000007901 in situ hybridization Methods 0.000 description 3
- 210000000265 leukocyte Anatomy 0.000 description 3
- 230000002934 lysing effect Effects 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 239000002207 metabolite Substances 0.000 description 3
- 238000003909 pattern recognition Methods 0.000 description 3
- 239000000902 placebo Substances 0.000 description 3
- 229940068196 placebo Drugs 0.000 description 3
- 238000001228 spectrum Methods 0.000 description 3
- 238000010183 spectrum analysis Methods 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- 230000014616 translation Effects 0.000 description 3
- 230000005751 tumor progression Effects 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- 208000005623 Carcinogenesis Diseases 0.000 description 2
- 108091033380 Coding strand Proteins 0.000 description 2
- 108700039887 Essential Genes Proteins 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 2
- 238000000636 Northern blotting Methods 0.000 description 2
- 239000013614 RNA sample Substances 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 229940041181 antineoplastic drug Drugs 0.000 description 2
- 210000000601 blood cell Anatomy 0.000 description 2
- 238000010804 cDNA synthesis Methods 0.000 description 2
- AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 2
- 230000036952 cancer formation Effects 0.000 description 2
- 231100000504 carcinogenesis Toxicity 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000007621 cluster analysis Methods 0.000 description 2
- 238000002790 cross-validation Methods 0.000 description 2
- 230000009089 cytolysis Effects 0.000 description 2
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000007274 generation of a signal involved in cell-cell signaling Effects 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 230000003100 immobilizing effect Effects 0.000 description 2
- 230000002055 immunohistochemical effect Effects 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 238000000370 laser capture micro-dissection Methods 0.000 description 2
- 238000007834 ligase chain reaction Methods 0.000 description 2
- 238000010801 machine learning Methods 0.000 description 2
- 238000001819 mass spectrum Methods 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 150000002739 metals Chemical class 0.000 description 2
- 230000001394 metastastic effect Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 238000010606 normalization Methods 0.000 description 2
- 238000002966 oligonucleotide array Methods 0.000 description 2
- 238000011275 oncology therapy Methods 0.000 description 2
- 230000036470 plasma concentration Effects 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 2
- 108091008601 sVEGFR Proteins 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 238000000672 surface-enhanced laser desorption--ionisation Methods 0.000 description 2
- 238000012549 training Methods 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 230000002485 urinary effect Effects 0.000 description 2
- CJIJXIFQYOPWTF-UHFFFAOYSA-N 7-hydroxycoumarin Natural products O1C(=O)C=CC2=CC(O)=CC=C21 CJIJXIFQYOPWTF-UHFFFAOYSA-N 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 102100021935 C-C motif chemokine 26 Human genes 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 241000195493 Cryptophyta Species 0.000 description 1
- 230000004544 DNA amplification Effects 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- 208000002699 Digestive System Neoplasms Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010014733 Endometrial cancer Diseases 0.000 description 1
- 206010014759 Endometrial neoplasm Diseases 0.000 description 1
- 108010067770 Endopeptidase K Proteins 0.000 description 1
- 206010014967 Ependymoma Diseases 0.000 description 1
- 101100218845 Escherichia coli (strain K12) bioH gene Proteins 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 206010064571 Gene mutation Diseases 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 102000005548 Hexokinase Human genes 0.000 description 1
- 108700040460 Hexokinases Proteins 0.000 description 1
- 101000897493 Homo sapiens C-C motif chemokine 26 Proteins 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- 208000007766 Kaposi sarcoma Diseases 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- 238000012773 Laboratory assay Methods 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 108091093037 Peptide nucleic acid Proteins 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 108091034057 RNA (poly(A)) Proteins 0.000 description 1
- 108020005093 RNA Precursors Proteins 0.000 description 1
- 108091028733 RNTP Proteins 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 208000002847 Surgical Wound Diseases 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 102000001742 Tumor Suppressor Proteins Human genes 0.000 description 1
- 108010040002 Tumor Suppressor Proteins Proteins 0.000 description 1
- 206010053614 Type III immune complex mediated reaction Diseases 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 101150046474 Vhl gene Proteins 0.000 description 1
- 108020005202 Viral DNA Proteins 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 238000000149 argon plasma sintering Methods 0.000 description 1
- 238000000376 autoradiography Methods 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 101150029327 bioB gene Proteins 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 239000000091 biomarker candidate Substances 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 210000000133 brain stem Anatomy 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000000919 ceramic Substances 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 239000012707 chemical precursor Substances 0.000 description 1
- 239000005081 chemiluminescent agent Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 125000001295 dansyl group Chemical group [H]C1=C([H])C(N(C([H])([H])[H])C([H])([H])[H])=C2C([H])=C([H])C([H])=C(C2=C1[H])S(*)(=O)=O 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 238000013501 data transformation Methods 0.000 description 1
- 238000003795 desorption Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 238000007877 drug screening Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 238000000295 emission spectrum Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000002875 fluorescence polarization Methods 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 239000012520 frozen sample Substances 0.000 description 1
- 238000003500 gene array Methods 0.000 description 1
- 238000012252 genetic analysis Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 238000009499 grossing Methods 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- ZRALSGWEFCBTJO-UHFFFAOYSA-O guanidinium Chemical compound NC(N)=[NH2+] ZRALSGWEFCBTJO-UHFFFAOYSA-O 0.000 description 1
- 210000004209 hair Anatomy 0.000 description 1
- 208000014617 hemorrhoid Diseases 0.000 description 1
- 238000010562 histological examination Methods 0.000 description 1
- 230000003463 hyperproliferative effect Effects 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 230000016178 immune complex formation Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 238000011532 immunohistochemical staining Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000012750 in vivo screening Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 210000003228 intrahepatic bile duct Anatomy 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000001459 lithography Methods 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- HWYHZTIRURJOHG-UHFFFAOYSA-N luminol Chemical compound O=C1NNC(=O)C2=C1C(N)=CC=C2 HWYHZTIRURJOHG-UHFFFAOYSA-N 0.000 description 1
- 210000005265 lung cell Anatomy 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- 229910052752 metalloid Inorganic materials 0.000 description 1
- 150000002738 metalloids Chemical class 0.000 description 1
- 238000001531 micro-dissection Methods 0.000 description 1
- 238000007431 microscopic evaluation Methods 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 238000003499 nucleic acid array Methods 0.000 description 1
- 238000007899 nucleic acid hybridization Methods 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 239000002751 oligonucleotide probe Substances 0.000 description 1
- 210000004197 pelvis Anatomy 0.000 description 1
- 210000003899 penis Anatomy 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 239000000816 peptidomimetic Substances 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 150000008300 phosphoramidites Chemical class 0.000 description 1
- 230000003711 photoprotective effect Effects 0.000 description 1
- 238000013439 planning Methods 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 210000004910 pleural fluid Anatomy 0.000 description 1
- 102000054765 polymorphisms of proteins Human genes 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 230000004952 protein activity Effects 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000000611 regression analysis Methods 0.000 description 1
- 210000005000 reproductive tract Anatomy 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 238000003345 scintillation counting Methods 0.000 description 1
- 238000007423 screening assay Methods 0.000 description 1
- 230000001235 sensitizing effect Effects 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 238000011895 specific detection Methods 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 238000013517 stratification Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 210000001138 tear Anatomy 0.000 description 1
- MPLHNVLQVRSVEE-UHFFFAOYSA-N texas red Chemical compound [O-]S(=O)(=O)C1=CC(S(Cl)(=O)=O)=CC=C1C(C1=CC=2CCCN3CCCC(C=23)=C1O1)=C2C1=C(CCC1)C3=[N+]1CCCC3=C2 MPLHNVLQVRSVEE-UHFFFAOYSA-N 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 238000012384 transportation and delivery Methods 0.000 description 1
- 230000004102 tricarboxylic acid cycle Effects 0.000 description 1
- 150000005691 triesters Chemical class 0.000 description 1
- ORHBXUUXSCNDEV-UHFFFAOYSA-N umbelliferone Chemical compound C1=CC(=O)OC2=CC(O)=CC=C21 ORHBXUUXSCNDEV-UHFFFAOYSA-N 0.000 description 1
- HFTAFOQKODTIJY-UHFFFAOYSA-N umbelliferone Natural products Cc1cc2C=CC(=O)Oc2cc1OCC=CC(C)(C)O HFTAFOQKODTIJY-UHFFFAOYSA-N 0.000 description 1
- 210000003954 umbilical cord Anatomy 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 230000004143 urea cycle Effects 0.000 description 1
- 206010046885 vaginal cancer Diseases 0.000 description 1
- 208000013139 vaginal neoplasm Diseases 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/475—Assays involving growth factors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Oncology (AREA)
- Medicinal Chemistry (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Hospice & Palliative Care (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Toxicology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US73585405P | 2005-11-14 | 2005-11-14 | |
| PCT/US2006/044117 WO2007059094A2 (en) | 2005-11-14 | 2006-11-14 | Methods for prediction and prognosis of cancer, and monitoring cancer therapy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009515553A true JP2009515553A (ja) | 2009-04-16 |
| JP2009515553A5 JP2009515553A5 (enExample) | 2009-12-10 |
Family
ID=37814675
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008541268A Pending JP2009515553A (ja) | 2005-11-14 | 2006-11-14 | 癌の予知および予後と、癌治療のモニタリング |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20070178494A1 (enExample) |
| EP (1) | EP1963849A2 (enExample) |
| JP (1) | JP2009515553A (enExample) |
| KR (1) | KR20080073745A (enExample) |
| CN (1) | CN101454668A (enExample) |
| AU (1) | AU2006315592A1 (enExample) |
| BR (1) | BRPI0618597A2 (enExample) |
| CA (1) | CA2629860A1 (enExample) |
| MX (1) | MX2008006239A (enExample) |
| RU (1) | RU2008123406A (enExample) |
| WO (1) | WO2007059094A2 (enExample) |
| ZA (1) | ZA200804509B (enExample) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2014506782A (ja) * | 2011-01-11 | 2014-03-20 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | 遺伝子の発現を分析することによって患者における癌の転帰を予測するための方法 |
| JP2014062914A (ja) * | 2008-10-21 | 2014-04-10 | Bayer Healthcare Llc | 肝細胞癌と関連するシグネチャ遺伝子を利用する検査方法、及び該方法に用いられるアレイ又はキット |
| JP2016518837A (ja) * | 2013-04-25 | 2016-06-30 | シービーエス バイオサイエンス，カンパニー，リミテッド | 肝細胞癌において分子標的治療の感受性を増加させるための分析方法 |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE556713T1 (de) | 1999-01-13 | 2012-05-15 | Bayer Healthcare Llc | Omega-carboxyarylsubstituierte-diphenyl- harnstoffe als p38-kinasehemmer |
| US8124630B2 (en) | 1999-01-13 | 2012-02-28 | Bayer Healthcare Llc | ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
| AU2003209116A1 (en) | 2002-02-11 | 2003-09-04 | Bayer Pharmaceuticals Corporation | Aryl ureas with angiogenesis inhibiting activity |
| US7557129B2 (en) | 2003-02-28 | 2009-07-07 | Bayer Healthcare Llc | Cyanopyridine derivatives useful in the treatment of cancer and other disorders |
| PT1636585E (pt) | 2003-05-20 | 2008-03-27 | Bayer Pharmaceuticals Corp | Diarilureias com actividade inibidora de cinase |
| NZ544920A (en) | 2003-07-23 | 2009-11-27 | Bayer Healthcare Llc | 4{4-[3-(4-chloro-3-trifluoromethylphenyl)-ureido]-3-fluorophenoxy}-pyridine-2-carboxylic acid methylamide and metabolites for the treatment and prevention of diseases and conditions |
| NZ561178A (en) | 2005-03-07 | 2010-11-26 | Bayer Schering Pharma Ag | Pharmaceutical composition comprising an omega-carboxyaryl substituted diphenyl urea for the treatment of cancer |
| AU2006304764A1 (en) * | 2005-10-21 | 2007-04-26 | Bayer Healthcare Llc | Methods for prediction and prognosis of cancer, and monitoring cancer therapy |
| CA2628091A1 (en) * | 2005-11-02 | 2007-05-18 | Bayer Healthcare Llc | Methods for prediction and prognosis of cancer, and monitoring cancer therapy |
| US20100008910A1 (en) * | 2006-09-12 | 2010-01-14 | John Chant | Methods and compositions for the diagnosis and treatment of cancer |
| AR062927A1 (es) * | 2006-10-11 | 2008-12-17 | Bayer Healthcare Ag | 4- [4-( [ [ 4- cloro-3-( trifluorometil) fenil) carbamoil] amino] -3- fluorofenoxi) -n- metilpiridin-2- carboxamida monohidratada |
| US20100311106A1 (en) * | 2008-01-25 | 2010-12-09 | Hartmann Lynn C | Quantitation of lobular involution for breast cancer risk prediction |
| GB0814722D0 (en) * | 2008-08-12 | 2008-09-17 | Ge Healthcare Ltd | Treatment monitoring |
| EP2156834A1 (en) * | 2008-08-08 | 2010-02-24 | S.I.F.I - Società Industria Farmaceutica Italiana - S.P.A. | Ophthalmic pharmaceutical compositions comprising Sorafenib for the treatment of neoangiogenic pathologies of the eye |
| WO2011042829A1 (en) * | 2009-10-07 | 2011-04-14 | Koninklijke Philips Electronics N.V. | Method of evaluating toxicity level of a patient undergoing a cancer treatment |
| CN102053150B (zh) * | 2009-10-30 | 2013-07-17 | 上海交通大学医学院附属瑞金医院 | 一种人成骨肉瘤干细胞相关抗原标记物及其应用 |
| BR112013001423A2 (pt) * | 2010-07-19 | 2016-05-24 | Hoffmann La Roche | método, método in vitro, uso e kit útil para realizar o método |
| US20130131136A1 (en) * | 2010-08-02 | 2013-05-23 | Nicolae Ghinea | Novel methods for predicting the responsiveness of a patient affected with a tumor to a treatment with a tyrosine kinase inhibitor |
| KR101437718B1 (ko) * | 2010-12-13 | 2014-09-11 | 사회복지법인 삼성생명공익재단 | 위암의 예후 예측용 마커 및 이를 이용하는 위암의 예후 예측 방법 |
| WO2013173384A1 (en) * | 2012-05-16 | 2013-11-21 | Dale Wong | Method and system for sorting biological samples |
| EP2971101A2 (en) * | 2013-03-15 | 2016-01-20 | Janssen Pharmaceutica N.V. | Assay for predictive biomarkers |
| RU2546035C1 (ru) * | 2014-04-15 | 2015-04-10 | Федеральное государственное бюджетное учреждение "Ростовский научно-исследовательский онкологический институт" Министерства здравоохранения Российской Федерации | Способ прогнозирования развития метастазов у больных меланомой кожи |
| RU2643761C1 (ru) * | 2017-08-10 | 2018-02-05 | Федеральное государственное бюджетное учреждение "Ростовский научно-исследовательский онкологический институт" Министерства здравоохранения Российской Федерации | Способ расчета прогноза раннего прогрессирования меланомы кожи |
| WO2019074920A1 (en) * | 2017-10-10 | 2019-04-18 | Oncocyte Corporation | METHODS AND COMPOSITIONS FOR THE DETECTION AND DIAGNOSIS OF BREAST CANCER |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6635421B1 (en) * | 1997-12-09 | 2003-10-21 | Children's Medical Center Corporation | Neuropilins and use thereof in methods for diagnosis and prognosis of cancer |
| US20030232400A1 (en) * | 2002-12-20 | 2003-12-18 | Susan Radka | Methods of screening subjects for expression of soluble receptors of vascular endothelial growth factor (VEGF) for use in managing treatment and determining prognostic outcome |
| WO2005009367A2 (en) * | 2003-07-17 | 2005-02-03 | Ambit Biosciences Corporation | Treatment of diseases with kinase inhibitors |
| CA2560269A1 (en) * | 2004-03-19 | 2005-09-29 | The Penn State Research Foundation | Combinatorial methods and compositions for treatment of melanoma |
-
2006
- 2006-11-14 JP JP2008541268A patent/JP2009515553A/ja active Pending
- 2006-11-14 AU AU2006315592A patent/AU2006315592A1/en not_active Abandoned
- 2006-11-14 WO PCT/US2006/044117 patent/WO2007059094A2/en not_active Ceased
- 2006-11-14 US US11/598,824 patent/US20070178494A1/en not_active Abandoned
- 2006-11-14 CA CA002629860A patent/CA2629860A1/en not_active Abandoned
- 2006-11-14 CN CNA2006800505936A patent/CN101454668A/zh active Pending
- 2006-11-14 BR BRPI0618597-5A patent/BRPI0618597A2/pt not_active IP Right Cessation
- 2006-11-14 MX MX2008006239A patent/MX2008006239A/es not_active Application Discontinuation
- 2006-11-14 RU RU2008123406/15A patent/RU2008123406A/ru not_active Application Discontinuation
- 2006-11-14 KR KR1020087014220A patent/KR20080073745A/ko not_active Withdrawn
- 2006-11-14 EP EP06837519A patent/EP1963849A2/en not_active Withdrawn
-
2008
- 2008-05-23 ZA ZA200804509A patent/ZA200804509B/xx unknown
Non-Patent Citations (3)
| Title |
|---|
| JPN6012023020; Ｔｏｈｏｋｕ Ｊ Ｅｘｐ Ｍｅｄ． Ｖｏｌ．１９５， Ｎｏ．２, 200110, ｐ．１０１-１１３ * |
| JPN6012023022; Ｅｕｒｏｐｅａｎ Ｊｏｕｒｎａｌ ｏｆ Ｃａｎｃｅｒ Ｓｕｐｐｌｅｍｅｎｔｓ Ｖｏｌ．３， Ｎｏ．２, 200510, ｐ．４２０ * |
| JPN6012023026; Ｐｒｏｃ Ａｍｅｒ Ａｓｓｏｃ Ｃａｎｃｅｒ Ｒｅｓ． Ｖｏｌ．４６, 200504, ｐ．１０８， Ａｂｓｔｒａｃｔ ＃４６４ * |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2014062914A (ja) * | 2008-10-21 | 2014-04-10 | Bayer Healthcare Llc | 肝細胞癌と関連するシグネチャ遺伝子を利用する検査方法、及び該方法に用いられるアレイ又はキット |
| JP2014506782A (ja) * | 2011-01-11 | 2014-03-20 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | 遺伝子の発現を分析することによって患者における癌の転帰を予測するための方法 |
| JP2017060515A (ja) * | 2011-01-11 | 2017-03-30 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | 遺伝子の発現を分析することによって患者における癌の転帰を予測するための方法 |
| JP2016518837A (ja) * | 2013-04-25 | 2016-06-30 | シービーエス バイオサイエンス，カンパニー，リミテッド | 肝細胞癌において分子標的治療の感受性を増加させるための分析方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| ZA200804509B (en) | 2009-05-27 |
| US20070178494A1 (en) | 2007-08-02 |
| AU2006315592A1 (en) | 2007-05-24 |
| EP1963849A2 (en) | 2008-09-03 |
| WO2007059094A3 (en) | 2008-01-24 |
| CN101454668A (zh) | 2009-06-10 |
| RU2008123406A (ru) | 2009-12-27 |
| CA2629860A1 (en) | 2007-05-24 |
| WO2007059094A2 (en) | 2007-05-24 |
| BRPI0618597A2 (pt) | 2011-09-06 |
| KR20080073745A (ko) | 2008-08-11 |
| MX2008006239A (es) | 2008-12-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009515553A (ja) | 癌の予知および予後と、癌治療のモニタリング | |
| US8329408B2 (en) | Methods for prognosis and monitoring cancer therapy | |
| US20040146921A1 (en) | Expression profiles for colon cancer and methods of use | |
| US20070065827A1 (en) | Gene expression profiles and methods of use | |
| US20130143762A1 (en) | Gene expression profiles and methods of use | |
| JP2007507243A (ja) | 遺伝子発現プロファイルおよび使用方法 | |
| WO2004078035A2 (en) | Expression profiles for breast cancer and methods of use | |
| US20070134670A1 (en) | Methods for prediction and prognosis of cancer, and monitoring cancer therapy | |
| WO2011146725A1 (en) | Biomarkers for a multikinase inhibitor | |
| US20040121375A1 (en) | Methods for prediction and prognosis of cancer, and monitoring cancer therapy | |
| WO2006032009A2 (en) | Methods for prediction and prognosis of cancer, and monitoring cancer therapy | |
| WO2005067650A2 (en) | Gene expression profiles and methods of use |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20091022 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20091022 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120515 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20121016 |